Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.

ABSTRACT:

Background

Increasing data indicate that HER2-positive (HER2 + ) breast cancer (BC) subtypes exhibit differential responses to targeted anti-HER2 therapy. This study aims to investigate these differences and the potential underlying molecular mechanisms.

Methods

A large cohort of BC patients (n = 7390) was utilised. The clinicopathological characteristics and differential gene expression (DGE) of HER2+ immunohistochemical (IHC) subtypes, specifically HER2 IHC 3+ and IHC 2 + /Amplified, were assessed and correlated with pathological complete response (pCR) and survival in the neoadjuvant and adjuvant settings, respectively. The role of oestrogen receptor (ER) status was also investigated.

Results

Compared to HER2 IHC 3+ tumours, BC patients with IHC 2 + /Amplified show

SUBMITTER: Atallah NM 

PROVIDER: S-EPMC10646129 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature